The immune prognostic index (ipi) effectively predicts prognosis and the benefit of postoperative chemotherapy in esophageal squamous cell carcinoma (ESCC) patients following minimally invasive esophagectomy (MIE). Patients with a low ipi demonstrated significantly better 5-year overall survival (OS) and disease-free survival (DFS) compared to those with a high ipi. Notably, adjuvant chemotherapy in stage III patients with a high ipi was associated with improved OS and DFS, marking ipi as a valuable prognostic tool.
Journal Article by Huang J, Chen C (…) Chen SC et 6 al. in BMC Gastroenterol
© 2025. The Author(s).